About Stoke Therapeutics
Stoke Therapeutics is a publicly listed company based in Bedford (United States) founded in 2014 by Adrian Krainer. It operates as a developer of antisense oligonucleotide drugs for treating inherited diseases by targeting RNA splicing. Stoke Therapeutics has raised $130.85 million across 3 funding rounds from investors including RTW Investments, RA Capital and Perceptive Advisors. The company has 128 employees. Its chief executive is Edward M Kaye. Its website stoketherapeutics.com draws about 11 thousand monthly visits. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro and 4 more; 9 of its 9 listed competitors have raised funding.
Company details
Stoke Therapeutics was founded in 2014 and is headquartered in Bedford, United States. Antisense oligonucleotide therapeutics are developed by the company to address inherited diseases through modulation of RNA splicing. The proprietary Targeted Augmentation of Nuclear Gene Output platform is utilized to enhance gene expression in a precise manner. A pipeline of candidates is being advanced for conditions affecting the central nervous system, eye, liver, and blood disorders.
- Headquarters Bedford, United States
- Employees 128
- Founders Adrian Krainer
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Phone•••• ••••
- Website stoketherapeutics.com
- Social LinkedIn X
- Legal Name Stoke Therapeutics, Inc.
- Annual Revenue$184.42 M (USD)404.5as on Dec 31, 2025
- Net Profit-$6.88 M (USD)92.26as on Dec 31, 2025
- EBITDA-$16.41 M (USD)83.07as on Dec 31, 2025
- Total Equity Funding$130.85M (USD)
in 3 rounds
- Latest Funding Round$90M (USD), Series B
Oct 2018
- InvestorsRTW Investments
& 6 more
- Employee Count128
Funding Insights of Stoke Therapeutics
Stoke Therapeutics has successfully raised a total of $130.85M across 3 strategic funding rounds. The most recent funding activity was a Series B round of $90 million completed in October 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $130.85M
- Total Rounds 3
- Last Round Series B — $90M
- First Round $850,000
(Nov 2014)
- Investors Count 7
All 3 funding rounds of Stoke Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2018 | $90M | Series B | – | RTW Investments | |
| Jan 2018 | $40M | Series A | – | Apple Tree Partners | – |
| Nov 2014 | $850,000 | Seed | – | – | – |
7 investors in total: 7 institutional.
Investors in Stoke Therapeutics
Stoke Therapeutics has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include RTW Investments, RA Capital and Perceptive Advisors.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life Sciences focused VC firm investing in the US | 2010 | rtwfunds.com | New York, United States | |
Apple Tree Partners is engaged in life sciences venture capital. | – | appletreepartners.com | - | |
Health-tech companies are targeted for venture capital investments. | 1999 | perceptivelife.com | New York, United States | |
Early stage investments focused VC firm | – | acks.com | - | |
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States | |
Operates as an employee-owned hedge fund focused on long/short equity strategies. | 2007 | redmilegroup.com | San Francisco, United States | |
Manages hedge funds with long/short equity and real estate strategies for investors. | 2004 | spherafund.com | Tel Aviv, Israel |
Investor details for Stoke Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Stoke Therapeutics
42 people are tracked at Stoke Therapeutics (25 in leadership, 6 in board & advisors, 11 in team); the tracked headcount is 128.
| Name | Role | Group |
|---|---|---|
Adrian Krainer | Co-Founder & Director | Leadership |
Edward M Kaye | CEO | Leadership |
Jacob Kach | Director, Program And Alliance Management | Leadership |
Carrie Condon | Clinical Science Senior Director | Leadership |
John Cosgriff | Head Of Compliance | Leadership |
Jessica Blumstein | Vice President, Global Market Access And Distribution | Leadership |
Stephen J. Tulipano | CFO | Leadership |
Emily Mahoney | Vp, Corporate Legal | Leadership |
Nitin V. | Vice President (Legal), Head of IP & Privacy | Leadership |
Barbara Sutter | Vice President, Controller | Leadership |
Wendy Spinazola Baccari | Senior Director HR Operations | Leadership |
Juergen Scharner | Associate Director | Leadership |
Christy Chaves Blaney | Senior Director, Head Of Talent Acquisition | Leadership |
Kimberly Parkerson | Senior Vice President, Head Of Neurology Clinical Development | Leadership |
Parisa S. | Vice President, Patient Advocacy & Policy | Leadership |
Barry S. Ticho | Chief Medical Officer | Leadership |
Terry Burns | Director, GCP Quality Compliance | Leadership |
Dawn Kalmar | Chief Of Corporate Affairs & Strategic Partnerships | Leadership |
Steven Gross | Senior Medical Director, Clinical Development - Ophthalmology | Leadership |
Charlene Brathwaite | Sr. Director, Clinical Operations | Leadership |
22 more people are available in the full profile.
Complete people profiles for Stoke Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Stoke Therapeutics
Stoke Therapeutics is a publicly listed company on the NASDAQ with ticker symbol STOK in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date19 Jun 2019
- Listed onNASDAQ: STOK
- Listed entityStoke Therapeutics, Inc.
- Exchange sectorHealth technology
- ISINUS86150R1077
- Share price$22.50 (-6.83% on the day) · 2026-10-13
- Market capitalisation$1.45B
- Price to earnings46.8
- EPS (diluted, trailing year)$-3.37
- Volume (last session)618,021
Financials of Stoke Therapeutics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $184.4M | -$6.9M | -$16.4M |
| 2024 | $36.5M | -$89.0M | -$96.9M |
| 2023 | $8.8M | -$104.7M | -$110.0M |
| 2022 | $12.4M | -$101.1M | -$100.8M |
| 2021 | – | -$85.8M | -$83.8M |
Detailed financial statements for Stoke Therapeutics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Stoke Therapeutics
4 dated milestones of Stoke Therapeutics across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Stoke Therapeutics is founded.
- Funding First funding round of $850K.
- Funding Latest funding round, Series B, of $90.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Stoke Therapeutics
Stoke Therapeutics has 9 listed competitors in our database, 9 of them funded. They include BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. | |
| cariboubio.com | 2011 | Berkeley, United States | $156.55M | 92 | Provider of cell therapies to treat cancer and hematologic conditions |
Detailed competitors of Stoke Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Stoke Therapeutics
The website of Stoke Therapeutics (stoketherapeutics.com) receives about 11.2K visits a month and ranks #1,762,974 among all websites worldwide, #2,395 in Biotechnology and Pharmaceuticals.
- Monthly visits11.2K
▼ 5.4% vs previous month
- Unique visitors5.6K
per month
- Global rank#1,762,974
among all websites
- Category rank#2,395
Health · Biotechnology and Pharmaceuticals
- Bounce rate36%
- Pages per visit2.4
- Average visit1 min 04 sec
- DevicesDesktop 37% · Mobile 63%
Websites whose visitors overlap most with Stoke Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| neurenpharma.com | 100% | 9.6K | #2,553,786 | View details | |
| drugdiscoverynews.com | 91% | – | #639,360 | View details | |
bioworld.com | bioworld.com | 91% | – | #311,180 | – |
rettsyndromenews.com | rettsyndromenews.com | 78% | – | #2,738,687 | – |
| checkrare.com | 69% | – | #1,556,758 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 12 similar websites and full traffic analytics for Stoke Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 12 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
10 companies that operate in the same segment as Stoke Therapeutics (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.34 B | USD 301.49 M | 1,372 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 562 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Stoke Therapeutics
Complete news archive for Stoke Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Stoke Therapeutics
Stoke Therapeutics was founded in 2014.
Stoke Therapeutics is headquartered in Bedford, United States.
Edward M Kaye is the current CEO of Stoke Therapeutics.
Stoke Therapeutics is a funded company, having raised a total of $130.85M across 3 funding rounds to date. The company's 1st funding round was a Seed of $850K, raised on Nov 2014.
Stoke Therapeutics has 128 employees.
Annual revenue of Stoke Therapeutics is $184.42M as on Dec 31, 2025.
Stoke Therapeutics was founded in 2014 and is headquartered in Bedford, United States. Antisense oligonucleotide therapeutics are developed by the company to address inherited diseases through modulation of RNA splicing. The proprietary Targeted Augmentation of Nuclear Gene Output platform is utilized to enhance gene expression in a precise manner. A pipeline of candidates is being advanced for conditions affecting the central nervous system, eye, liver, and blood disorders.
Stoke Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Yes, Stoke Therapeutics is publicly traded on NASDAQ under the ticker symbol STOK.
Stoke Therapeutics has 7 investors. Key investors include RTW Investments, RA Capital, Perceptive Advisors, Apple Tree Partners, and Acks.